This presentation will define patient-reported outcomes (PROs), discuss how PROs have been used in research, and identify opportunities to translate PROs into the clinical setting.
This presentation will review ethical issues that are encountered in daily practice, implications and the implementation of an Ethics Liasion Program.
This presentation will provide an update on administering Blinatumomab to pediatric patients, including challenges, and updates to practice as a result of lessons learned over the past decade.
This presentation will review the historical late effects seen with conventional therapy for High-Risk Neuroblastoma. It will also explore some of the new data that has come out of the most recent COG "LEAHRN" (Late Effects after High-Risk Neuroblastoma) study. The aim of this study was to examine late effects after modern neuroblastoma treatment with immunotherapy.
This presentation will: (1) identify common skin manifestations and rare side effects when administering MEK inhibitors; (2) Provide anticipatory guidance, prophylaxis skin care for patients and families; (3) Share case studies to understand various medical management for common or chronic skin manifestations.
This presentation will focus on recent research into the distress experience of the parents of children with acute leukemia, conducted at the Hospital for Sick Children and the Princess Margaret Cancer Centre. Specifically, this presentation will review results from a prospective longitudinal study of parental traumatic stress and related health outcomes, as well as results from a pilot trial of a psychotherapeutic intervention to manage this distress.
At least half of young adult survivors of childhood cancer struggle with at least one major sexual problem within two years of diagnosis. As essential providers in the care of these patients and their loved ones, nurses can lo longer wait for "someone else" to address these issues. Nurses are well positioned to discuss sensitive topics such as sexuality concerns with patients because of their compassion, knowledge, established trust and access to AYA cancer patients. This session will provide participants with strategies to initiate these uncomfortable conversations and identify available resources for patients and providers.
Children and youth with autism spectrum disorder (ASD) may face unique challenges coping with the diagnosis and treatment of cancer, healthcare encounters and procedures, and hospitalization. This session will discuss how to adapt care and develop individualized strategies to support children and youth with ASD and cancer throughout their journey.
How has supportive care changed over 40 years? Does it really make a difference or is it just glitter and sparkles? When is a great idea not a good thing? What haven't you asked that you want to? These questions, to some extent, will have answers offered.
One of the strategic objectives of the Childhood Cancer Care Plan: A Roadmap for Ontario 2018- 2023 is to promote enhanced supportive care through clinical practice guideline (CPG) development and uptake. We will describe the development and implementation of institution specific supportive care pathways for infection prevention and management in the POGO network. We will also describe efforts to harmonize the care provided to children with cancer across Ontario in terms of supportive care for infection prevention and management.
SPECIAL INTEREST SESSIONS
Special interest sessions take place concurrently. There are four to choose from and they are offered on both Friday and Saturday. These sessons are designed to be interactive and conducive to discussion and collective problem-solving.
Using patient-based scenarios, this session will focus on the complexities and emerging opportunities in the management of Hodgkin lymphoma in childhood, adolescents, and young adults. In addition, participants are invited to engage in a discussion of the role of patient reported outcomes, shared decision making and drug access in treatment decisions.
Despite survival improvements owed to traditional cytotoxic chemotherapy in pediatric solid tumors in the past 4 decades, patients with relapsed or refractory disease continue to have poor outcomes. There is a clear need therefore for novel therapeutics and targeted agents in this difficult to treat patient population. This session will use a series of solid tumor cases to explore the considerations in using novel therapeutics both within and outside of clinical trial settings.
This presentation will discuss the history of blinatumomab in both adult and pediatric acute lymphoblastic leukemia, and what the future may or may not hold for the role of this agent.
This presentation will provide an overview of the current evidence related to the mental health of pediatric cancer patients, emphasizing the increased burden of mental health difficulties post-COVID. It will also include exciting new initiatives to support the mental health needs of pediatric cancer patients.
This presentation will describe the current and future state of Youth Wellness Hubs Ontario as a system-wide initiative to support the health and wellbeing of youth aged 12-25 years. Available mental health, substance use, health, and other community and social support across the province will be outlined. Future plans to enhance services and outcomes through operating as a learning health system will also be described.
A Cost-Utility Analysis of Nelarabine for the First-Line Treatment of T-Cell Acute Lymphoblastic Leukemia
Roaa Shoukry, The Hospital for Sick Children
Emotion and Symptom-focused Engagement (EASE): Qualitative Evaluation of a Psychosocial Intervention for Family Caregivers of Children with Acute Leukemia
Ally Yu, Princess Margaret Cancer Centre
POGO Satellite Clinic Program: A data-driven approach to monitoring and improving access to high quality care closer to home
Felicia Leung, POGO
Despite standardized care on multi-center clinical trials, children exposed to adverse social determinants of health are more likely to relapse and die, and their families suffer inferior psychosocial outcomes. This presentation will discuss opportunities to improve outcomes in pediatric cancer by systematically considering social determinants of health as risk factors for poor outcome and integrating them into the existing robust clinical trial and basic science models of discovery and care in pediatric cancer.
TP53 Mutational Clusters Stratify the Li-Fraumeni Syndrome Spectrum and Reveal an Osteosarcoma-Prone Subgroup
Nicholas Fischer, The Hospital for Sick Children
Innovative Backpacks for Kids and Teens Receiving Blinatumomab
Alia Petropoulos, The Hospital for Sick Children
Bereaved Children's Questions About Illness, Death and Grief: What they Wonder, and How to Respond
Ashwini Pugazhendhi, McMaster University
Increased Probability of Relapse Associated with Thromboembolism and Bloodstream Infections during Primary Therapy for Acute Lymphblastic Leukemia in Children: Results of a Provincial Prospective Study
Louise Guolla, McMaster University
Through the use of case examples, this presentation will review some of the complexities in managing neuroblastoma including initial decision-making relating to risk stratification, new treatment approaches and the challenges in treating patients with relapsed high-risk disease.
SPECIAL INTEREST SESSIONS
Special interest sessions take place concurrently. There are four to choose from and they are offered on both Friday and Saturday. These sessons are designed to be interactive and conducive to discussion and collective problem-solving.
Using patient-based scenarios, this session will focus on the complexities and emerging opportunities in the management of Hodgkin lymphoma in childhood, adolescents, and young adults. In addition, participants are invited to engage in a discussion of the role of patient reported outcomes, shared decision making and drug access in treatment decisions.
Despite survival improvements owed to traditional cytotoxic chemotherapy in pediatric solid tumors in the past 4 decades, patients with relapsed or refractory disease continue to have poor outcomes. There is a clear need therefore for novel therapeutics and targeted agents in this difficult to treat patient population. This session will use a series of solid tumor cases to explore the considerations in using novel therapeutics both within and outside of clinical trial settings.
There have been tremendous clinical and scientific advances in the field of pediatric oncology over the last 40 years, but there is always more to do. Join us for a dynamic discussion featuring a range of expert opinions on setting priorities and harnessing available resources to continually improve care for pediatric cancer patients, survivors and their families.
This presentation will focus on a new RNA-based platform, developed in the Shlien lab at The Hospital for Sick Children, which has the potential to become a universal diagnostic test for childhood cancer.
